Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Karen A. Gelmon
No relevant relationships to disclose
Judy-Anne W. Chapman
No relevant relationships to disclose
Shuzhen Liu
Research Funding - NanoString Technologies
Margot J. Burnell
Other Remuneration - Roche
Mark Norman Levine
No relevant relationships to disclose
Kathleen I. Pritchard
No relevant relationships to disclose
Timothy Joseph Whelan
No relevant relationships to disclose
Hope S. Rugo
No relevant relationships to disclose
Kathy S. Albain
Consultant or Advisory Role - NanoString Technologies
Edith A. Perez
No relevant relationships to disclose
Shakeel Virk
No relevant relationships to disclose
Patti O'Brien
No relevant relationships to disclose
Lois E. Shepherd
No relevant relationships to disclose
Torsten O. Nielsen
Consultant or Advisory Role - Bioclassifier; NanoString Technologies
Stock Ownership - Bioclassifier
Research Funding - NanoString Technologies
Other Remuneration - NanoString Technologies